NASDAQ:MCRB Seres Therapeutics Q2 2026 Earnings Report $2.94 +0.01 (+0.34%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$3.00 +0.06 (+1.87%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Seres Therapeutics EPS ResultsActual EPS$0.47Consensus EPS -$2.18Beat/MissBeat by +$2.65One Year Ago EPSN/ASeres Therapeutics Revenue ResultsActual Revenue$0.74 millionExpected Revenue$0.18 millionBeat/MissBeat by +$557.00 thousandYoY Revenue GrowthN/ASeres Therapeutics Announcement DetailsQuarterQ2 2026Date8/5/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time7:00AM ETUpcoming EarningsSeres Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Seres Therapeutics Earnings HeadlinesSeres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?September 30 at 2:41 AM | americanbankingnews.comSeres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from S&P Global BMI IndexSeptember 20, 2026 | marketscreener.comMThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 3 at 1:00 AM | Banyan Hill Publishing (Ad)Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 8, 2026 | globenewswire.comSeres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 1, 2026 | globenewswire.comCanaccord Genuity Reaffirms Their Buy Rating on Seres Therapeutics (MCRB)August 20, 2026 | theglobeandmail.comSee More Seres Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Seres Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seres Therapeutics and other key companies, straight to your email. Email Address About Seres TherapeuticsSeres Therapeutics (NASDAQ:MCRB) is a biotechnology company focused on developing live biotherapeutics designed to treat diseases by restoring or modifying the human microbiome. The company’s research has centered on microbial communities that may influence immune function, gastrointestinal health and disease progression. Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was developed to reduce the recurrence of Clostridioides difficile infection in adults following antibacterial treatment. The orally administered therapy uses purified bacterial spores to help restore the gut microbiome and received approval from the U.S. Food and Drug Administration in 2023. Founded in 2010 and headquartered in Cambridge, Massachusetts, Seres has pursued microbiome-based therapies for gastrointestinal and immune-mediated conditions. The company’s programs have included treatments intended to support patients undergoing hematopoietic stem cell transplantation and other therapies that can disrupt the intestinal microbiome. Seres has served primarily the U.S. market through its development and commercialization activities and has worked with pharmaceutical and healthcare partners to advance its products.View Seres Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
